Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Contract Win

20 Jul 2005 08:30

Angle PLC20 July 2005 For Immediate Release 20 July 2005 ANGLE plc Wins Contract With The BioBusiness Alliance of Minnesota ANGLE plc, the venture management and consulting company specialising in thecommercialisation of technology and the development of technology-based industryis pleased to announce that its US Consulting and Management division has won acontract with The BioBusiness Alliance of Minnesota, worth $200,000, to conducta comprehensive assessment of the state's biobusiness capabilities. The BioBusiness Alliance of Minnesota is an industry-driven, businessdevelopment organisation of representatives from established and emergingMinnesota companies, universities and government. It is devoted to building thebioscience industry, retaining and creating jobs and economic growth, andpositioning Minnesota as a global leader in biobusiness. The Minnesotabiobusiness industry includes many World-class businesses and institutions suchMedtronic, 3M and the Mayo Clinic. The information from the six month assessment, which will conclude in the fourthquarter of 2005, will benchmark Minnesota against other countries and states.The outcome of the process will identify the State's strengths and developmentneeds, and provide recommendations to target specific areas of biobusiness inwhich Minnesota can compete as a global leader. These recommendations willreflect the convergence of technologies, products, and markets that exist in theState, and identify Minnesota's opportunity areas for growth. ANGLE established a Minnesota office in August 2004 in recognition of thesignificant business potential it believes exists in this State. ANGLE waschosen following a rigorous national and international selection process. ANGLEwas selected for their significant experience both in conducting assessments inthe U.S. and internationally, and for their consulting expertise in thetechnology industry. Dr. Gary P. Evans, CEO of ANGLE's US Operations, said: "We are delighted that ANGLE has been selected to deliver this innovative,industry-driven assessment of Minnesota's biobusiness capabilities. We lookforward to working with the BioBusiness Alliance team to take the first step inthe long-term planning and development of a biobusiness strategy for Minnesota." Andrew Newland, Chief Executive of ANGLE plc, said: "This contract is a great example of ANGLE's continuing expansion within theUnited States. The Minnesota region is a prosperous biobusiness arena and thiscontract will position ANGLE alongside some of the biggest names in the market.We expect that Minnesota will emerge as a further key platform for our Venturesbusiness in the US." - ENDS - For further information ANGLE plcAndrew Newland, Chief Executive Tel: +44(0)1483 295830Lisa Smith, Principal Executive, US Operations Tel: +1 301 524 5654 Buchanan Communications Tel: +44 (0)20 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to EditorsFounded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This includes extensiveexpertise in the commercialization of technology, new company formation,investment and corporate finance, Research Park and incubator development andmanagement, and delivery of economic development programs. ANGLE operates fromoffices in the UK, the US and the Middle East. ANGLE is listed on AIM (AGL.L); further information can be found onwww.ANGLEplc.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
26th Mar 20184:35 pmRNSPrice Monitoring Extension
26th Mar 20187:00 amRNSResearch Update
6th Feb 20187:00 amRNSANGLE plc: RESEARCH GRANT FROM ABBOTT
31st Jan 20187:00 amRNSInterim Results
16th Jan 20187:00 amRNSWEBINAR:USING PARSORTIX TO TEST DRUGS ON LIVE CTCS
10th Jan 201810:16 amRNSNotice of Results
8th Jan 20187:00 amRNSANGLE plc:Prostate cancer ARV7 treatment biomarker
27th Dec 201711:49 amRNSHolding(s) in Company
12th Dec 20177:00 amRNSTransfer of Lock-in Shares
8th Dec 20177:00 amRNSPARSORTIX POTENTIAL IN METASTATIC BREAST CANCER
28th Nov 20177:00 amRNSParsortix enables CTC molecular characterisation
23rd Nov 20177:00 amRNSPHILIPS COLLABORATION IN BREAST AND RECTAL CANCER
17th Nov 20174:06 pmRNSHolding(s) in Company
16th Nov 20178:23 amRNSTotal Voting Rights and Covington Subscription
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
6th Nov 20177:00 amRNSHolding(s) in Company
2nd Nov 201710:04 amRNSHolding(s) in Company
1st Nov 20178:12 amRNSANGLE: Completion of Fundraising and Acquisition
31st Oct 20172:18 pmRNSResult of AGM
30th Oct 201710:31 amRNSResult of General Meeting
26th Oct 20178:10 amRNSTotal Voting Rights
23rd Oct 20177:00 amRNSParsortix harvests cancer cells from bone marrow
20th Oct 20173:05 pmRNSNotice of AGM
17th Oct 20177:00 amRNSANGLE: 7th Peer Reviewed Publication On Parsortix
12th Oct 20177:00 amRNSProposed further subscription for £2.8 million
9th Oct 20177:02 amRNSCTCs harvested with Parsortix grown in laboratory
9th Oct 20177:01 amRNSPotential new analytical protocol using Parsortix
9th Oct 20177:00 amRNSParsortix Showcased at CTC Conference
5th Oct 201711:46 amRNSResults of Fundraising
5th Oct 20177:00 amRNSAcquisition and Fundraising
13th Sep 20175:36 pmRNSHolding(s) in Company
13th Sep 20177:00 amRNSExclusive worldwide option over megakaryocyte IP
11th Sep 20177:00 amRNSCo-Marketing Partnership with QIAGEN
5th Sep 20177:00 amRNSChange of Adviser
4th Sep 20177:00 amRNSNew Research with Parsortix
27th Jul 20177:00 amRNSPreliminary Results
20th Jul 20171:00 pmRNSPreclinical Study Presented At Tumor Boston Summit
6th Jul 201710:05 amRNSNotice of Results
4th Jul 20177:00 amRNSSuccessful Headline Data in Ovarian Cancer Studies
15th Jun 20177:00 amRNSParsortix breakthrough in prostate cancer
5th Jun 20177:00 amRNSSuccess with Parsortix in Colorectal Cancer
3rd May 20177:00 amRNSBusiness Update
4th Apr 20177:00 amRNSHolding(s) in Company
3rd Apr 20177:00 amRNSParsortix enables analysis in head and neck cancer
30th Mar 20177:00 amRNSProstate Cancer Update
14th Feb 201711:39 amEQSEdison issues outlook on Angle
13th Feb 20177:00 amRNSSelected for European Cancer ID Programme
26th Jan 20177:01 amRNSInterim Evaluation of Ovarian Cancer Study
26th Jan 20177:00 amRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.